110 results
424B3
ATXI
Avenue Therapeutics, Inc.
10 May 24
Prospectus supplement
4:53pm
information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … ) and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits
424B5
ATXI
Avenue Therapeutics, Inc.
10 May 24
Prospectus supplement for primary offering
4:52pm
the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic
8-K
EX-4.3
ATXI
Avenue Therapeutics, Inc.
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i
8-K
EX-10.1
fuqvqk zz
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.1
qxogdo
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.2
5l3io4kzchqn1xb tlf8
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
424B3
w9esdhx3li2fi t0mth
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-4.2
i75awh36 elof2iz
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
l5m70gp3u6gyp3c
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
j7iw5r 04u
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
uj9q674rd ud
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
6fm3jom
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
z743y7j0a
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm